Watch BIOE. Know when insiders buy.
One email the day a filing lands. Free.
BIOE
Bio Essence Corp
0.18
−0.01 −4.21%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.8MP/E —DIV YIELD —FCF YIELD —REV TTM $2.9M +416.6%NET INCOME $1.5MNET DEBT $28K52W 0.05 – 0.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $795K | +206.7% | 59.2% | $279K | $270K | +351.2% | — | $60K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $501K | +2155.8% | 63.8% | $216K | $205K | — | — | −$412K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | $1.5M | +902.6% | 77.3% | $1M | $1M | — | — | $1.2M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | $137K | +1.6% | 70.0% | $14K | $13K | — | — | $187K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $259K | +521.5% | 65.1% | $61K | $60K | — | 0.00 | $168K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $22K | — | 92.8% | −$205K | −$206K | −253.6% | -0.01 | −$26K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $148K | — | 72.4% | $4K | −$28K | — | 0.00 | $423K | — | — | Mar 27 |
| Q3 2024 · Sep 30 | $135K | −13.5% | 60.1% | −$146K | −$1.2M | — | -0.03 | $357K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $42K | — | 70.0% | −$165K | −$216K | — | -0.01 | $15K | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$152K | $134K | — | 0.00 | −$172K | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | −$205K | — | 9.3% | −$195K | −$194K | — | -0.01 | −$204K | $0 | −$204K | Mar 28 |
| Q3 2023 · Sep 30 | $156K | — | 13.0% | −$83K | −$315K | — | -0.01 | −$345K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.9M | 75.3% | $900K | $896K | 47.2% | — | $1.6M | — | — | — | — |
| FY2024 · to Dec 31 | $324K | 67.0% | −$459K | −$1.3M | -404.0% | -0.03 | $624K | — | — | — | — |
| FY2023 · to Dec 31 | $552K | 50.3% | −$346K | −$972K | -176.2% | -0.03 | −$1M | $4K | −$1M | — | — |
| FY2022 · to Dec 31 | $622K | 52.8% | −$511K | −$810K | -130.3% | -0.02 | −$703K | $4K | −$707K | — | — |
| FY2021 · to Dec 31 | $888K | 33.6% | −$858K | −$648K | -72.9% | -0.02 | −$1.3M | $119K | −$1.4M | — | — |
| FY2020 · to Dec 31 | $959K | 23.7% | −$833K | −$596K | -62.2% | -0.02 | −$733K | $7K | −$740K | — | — |
Every number comes from Bio Essence Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.